StressMarq Biosciences

Founded in 2007, StressMarq Biosciences is a market leader in the development and commercialisation of unique fibrilised and oligomeric protein preparations for use in neurodegenerative disease research. With a portfolio including proteins such as alpha synuclein, tau, amyloid beta, SOD1 and TTR, StressMarq Biosciences focuses on developing cutting-edge life science research products that assist in the study of Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

Europa Biosite’s subsidiaries distribute for StressMarq Biosciences in Austria, Belgium, Luxembourg, Switzerland and the Netherlands.